Pharmaceutical

STAT+: Not-for-profit CommonSpirit Health paid its CEO ...

Not-for-profit CommonSpirit Health paid its former CEO, Lloyd Dean, $35.5 millio...

Mishmash of how U.S. heat deaths are counted complicate...

Experts say a mishmash of ways more than 3,000 counties calculate heat deaths me...

Long-term exposure to particulates from wildfire smoke ...

Researchers found strong correlation between fine particulates from wildfire smo...

STAT+: Pharmalittle: White House drug-shortage panel is...

The family of Henrietta Lacks, whose “immortal cell line” has led to medical inn...

STAT+: What’s behind the recent surge in Apellis’ stock...

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief amo...

STAT+: In the case of a devastating disease, the FDA we...

An experimental drug for FOP symbolizes a future in which years of research, adv...

STAT+: After Optum Health’s lowest profit margin in a d...

Just weeks after UnitedHealth's Optum posted its lowest profit margin in a decad...

STAT+: Hospitals are dialing back on venture capital in...

Once seen as a way to innovate, many hospitals are now dialing back on venture c...

Listen: How Long Island became the ‘eugenics capital of...

In a new episode of "Color Code," STAT explores the history of a Long Island lab...

STAT+: FDA warns AstraZeneca over misleading promotiona...

The FDA scolded AstraZeneca for making misleading claims about the effectiveness...

STAT+: SEC wants to know if key supplier of research mo...

The move comes as the Department of Justice probes a Cambodian smuggling ring th...

America’s ERs struggle with timely care for stroke pati...

Black, Hispanic, and female patients, as well as those over 80 all experienced l...

YouTube cracks down on misinformation on cancer treatment

YouTube’s health division is stepping up its effort to combat medical informatio...

STAT+: Pharmalittle: Amazon Pharmacy offers insulin dis...

Amazon Pharmacy will begin automatically applying manufacturer coupons to more t...

Radiation, a mainstay of cancer treatment, begins a fad...

“There are situations now on an individual patient basis where radiation may not...

STAT+: BMS, looking to build a market for a heart drug,...

As Bristol Myers Squibb works to build Camzyos into a blockbuster drug, it has p...